2. Search Result
Search Result
Results for "

p-MET

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15959
    Savolitinib
    Maximum Cited Publications
    7 Publications Verification

    Volitinib; HMPL-504; AZD-6094

    		 c-Met/HGFR Cancer
    Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity .
    Savolitinib
  • HY-138696
    Zanzalintinib
    1 Publications Verification

    XL092

    		 TAM Receptor c-Met/HGFR VEGFR Cancer
    Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .
    Zanzalintinib
  • HY-18696
    AMG-337
    3 Publications Verification

    		 c-Met/HGFR Caspase Apoptosis Cancer
    AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC50 values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis .
    AMG-337
  • HY-W111226
    Fmoc-His(3-Me)-OH

    		Amyloid-β Amino Acid Derivatives Cardiovascular Disease Neurological Disease
    Fmoc-His (3-Me)-OH is a histidine derivative with a methylated imidazole group. Fmoc-His (3-Me)-OH can be used for the synthesis of the chemically modified tripeptide His (3-methyl)-Arg-Trp (H (3-Me)-RW). Fmoc-His (3-Me)-OH serves as a resin in Fmoc solid-phase synthesis for the generation of the His-(3-Me)-Gly-Lys peptide. Fmoc-His (3-Me)-OH is a building block for the synthesis of NAHIS02-(p-Met). Fmoc-His (3-Me)-OH can be applied in research related to Alzheimer's disease .
    Fmoc-His(3-Me)-OH
  • HY-P990661
    SAIT-301

    		c-Met/HGFR ERK PERK Cancer
    SAIT-301 is a Met-targeting monoclonal antibody. SAIT-301 inhibits Met activation, induces downregulated expression of phosphorylated Met(p-Met) and phosphorylated ERK(p-ERK), and reduces EGR-1 expression. SAIT-301 inhibits the migration and invasion of nasopharyngeal carcinoma cells. SAIT-301 is applicable to relevant research on nasopharyngeal carcinoma. For the isotype control of SAIT-301, refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    SAIT-301

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: